What is ABECMA? ABECMA (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least four kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
The most common side effects of ABECMA are fatigue, fever (100.4°F/38°C or higher), chills/shivering, severe nausea or diarrhea, decreased appetite, headache, dizziness/lightheadedness, confusion, difficulty speaking or slurred speech, cough, difficulty breathing, and fast or irregular heartbeat.
Overall response is the term
used when there is a meaningful
decrease in signs of myeloma.
This includes partial response (a
decrease in the amount of
myeloma in the body) and
Complete response (CR) or
better is a term that means there
is no detectable evidence of
tumor in the body (all signs of
myeloma have disappeared). A
CR does not mean the myeloma
has been cured.
Follow-up time is the time
between infusion and the most
recent time point when data on
the patient’s outcomes were
83% of patients who responded to ABECMA responded within one month of their infusion (60 out of 72 patients; the range was 0.5 to 2.9 months).
While regular check-ins with your healthcare team are still required, the following are NOT required for your MM while responding to ABECMA:
Duration of response is the
length of time a patient
continues to respond to therapy
without their multiple myeloma
growing or spreading.
The median is the middle
number in a set of data. This
means half the numbers in the
group are more than the median
and half the numbers in a group
are less than the median.
CAR=chimeric antigen receptor; RRMM=relapsed or refractory multiple myeloma.